Seer (NASDAQ:SEER) CFO David Horn Sells 7,303 Shares of Stock

Seer, Inc. (NASDAQ:SEER) CFO David Horn sold 7,303 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $1.69, for a total value of $12,342.07. Following the transaction, the chief financial officer owned 493,959 shares of the company’s stock, valued at approximately $834,790.71. The trade was a 1.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Seer Stock Up 5.4%

Shares of Seer stock opened at $1.77 on Friday. The firm has a market cap of $99.86 million, a price-to-earnings ratio of -1.43 and a beta of 1.63. The business has a 50-day moving average price of $1.80 and a 200-day moving average price of $1.87. Seer, Inc. has a twelve month low of $1.65 and a twelve month high of $2.41.

Seer (NASDAQ:SEER) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, hitting the consensus estimate of ($0.30). The company had revenue of $2.79 million during the quarter, compared to analyst estimates of $3.60 million. Seer had a negative return on equity of 26.58% and a negative net margin of 464.78%.

Analyst Ratings Changes

Several brokerages have issued reports on SEER. Weiss Ratings reissued a “sell (d-)” rating on shares of Seer in a research note on Tuesday, April 21st. Canaccord Genuity Group assumed coverage on shares of Seer in a research note on Monday, May 4th. They set a “buy” rating and a $4.00 price target for the company. Finally, TD Cowen raised shares of Seer to a “strong-buy” rating in a research note on Monday, April 13th. Two research analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $4.00.

Institutional Investors Weigh In On Seer

A number of large investors have recently made changes to their positions in the stock. Rangeley Capital LLC boosted its holdings in Seer by 821.5% in the first quarter. Rangeley Capital LLC now owns 184,302 shares of the company’s stock valued at $310,000 after purchasing an additional 164,302 shares during the last quarter. Corient Private Wealth LLC purchased a new stake in shares of Seer during the 4th quarter worth about $116,000. Quadrature Capital Ltd purchased a new stake in shares of Seer during the 4th quarter worth about $101,000. Barclays PLC lifted its stake in Seer by 685.0% in the 4th quarter. Barclays PLC now owns 60,717 shares of the company’s stock valued at $111,000 after buying an additional 52,982 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in Seer in the 4th quarter valued at about $85,000. 75.20% of the stock is owned by hedge funds and other institutional investors.

About Seer

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.